Carol J Whelan
Overview
Explore the profile of Carol J Whelan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
3883
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chiaro G, Stancanelli C, Koay S, Vichayanrat E, Sander L, Ingle G, et al.
Clin Auton Res
. 2024 May;
34(3):341-352.
PMID: 38769233
Background: The cardiomyopathic and neuropathic phenotype of hereditary transthyretin amyloidosis are well recognized. Cardiovascular autonomic dysfunction is less systematically and objectively assessed. Methods: Autonomic and clinical features, quantitative cardiovascular autonomic...
2.
Razvi Y, Ioannou A, Patel R, Chacko L, Karia N, Riefolo M, et al.
Eur J Heart Fail
. 2023 Nov;
26(2):383-393.
PMID: 37953725
Aims: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure. A total of 3-4% of individuals of African descent carry a TTR gene mutation encoding the p.(V142I)...
3.
Fontana M, Gilbertson J, Verona G, Riefolo M, Slamova I, Leone O, et al.
N Engl J Med
. 2023 Jun;
388(23):2199-2201.
PMID: 37285532
No abstract available.
4.
Cohen O, Sathyanath A, Petrie A, Ravichandran S, Law S, Manwani R, et al.
Heart
. 2022 Jun;
108(20):1616-1622.
PMID: 35764371
Objectives: In AL amyloidosis, organ response assessment is based on surrogates (eg, cardiac biomarkers). An objective functional test, such as the 6 min walk test (6MWT), capturing overall clinical improvement,...
5.
Law S, Bezard M, Petrie A, Chacko L, Cohen O, Ravichandran S, et al.
Eur Heart J
. 2022 May;
43(27):2622-2632.
PMID: 35608040
Aims: Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly diagnosed at an early stage of the disease natural history, defined as National Amyloidosis Centre (NAC) ATTR Stage I. The natural history of...
6.
Cohen O, Blakeney I, Law S, Ravichandran S, Gilbertson J, Rowczenio D, et al.
Amyloid
. 2022 May;
29(4):237-244.
PMID: 35502644
Introduction: Hereditary apolipoprotein A-I (AApoAI) amyloidosis is a rare heterogeneous disease with variable age of onset and organ involvement. There are few series detailing the natural history and outcomes of...
7.
Cohen O, Ismael A, Pawarova B, Manwani R, Ravichandran S, Law S, et al.
Eur Heart J
. 2021 Sep;
43(4):333-341.
PMID: 34472567
Aims: Cardiac involvement, a major determinant of prognosis in AL (light-chain immunoglobulin) amyloidosis, is characterized by an impairment of longitudinal strain (LS%). We sought to evaluate the utility of LS%...
8.
Rezk T, Salota R, Gan J, Lachmann H, Fontana M, Siew K, et al.
Br J Haematol
. 2021 Aug;
194(6):1016-1023.
PMID: 34374069
Renal risk stratification in systemic immunoglobulin light-chain (AL) amyloidosis is according to estimated glomerular filtration rate (eGFR) and urinary protein creatinine ratio (uPCR), the latter attributed to glomerular dysfunction, with...
9.
Quarta C, Zheng J, Hutt D, Grigore S, Manwani R, Sachchithanantham S, et al.
Eur Heart J Cardiovasc Imaging
. 2021 Jul;
22(11):1304-1311.
PMID: 34254119
Aims: Technetium-99m-labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD scintigraphy) is recognized as highly accurate for the non-invasive diagnosis of transthyretin (ATTR) cardiac amyloidosis (CA). A proportion of patients with immunoglobulin light chain (AL)...
10.
Law S, Petrie A, Chacko L, Cohen O, Ravichandran S, Gilbertson J, et al.
Heart
. 2021 May;
108(6):474-478.
PMID: 33990410
Objectives: Wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM) is a progressive and fatal condition. Although prognosis can be determined at the time of diagnosis according to National Amyloidosis Centre (NAC) transthyretin amyloidosis...